Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases

NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) is presenting in vivo preclinical results at the Society for Neuroscience’s annual meeting illuminating the role of sigma-2 (σ-2) receptor modulators, including CT1812, in models of Alzheimer's and Parkinson’s diseases.

The effect of two chemically distinct σ-2 receptor modulators in a mouse model of Alzheimer’s disease on gene and protein expression are presented. Data shed light on the molecular mechanisms and build upon previous studies in this same mouse model where Cognition’s lead candidate, CT1812 was previously shown to decrease binding of Aβ oligomers to neuronal synapses and ameliorate cognitive deficits.  

Separately, work supported by a Michael J. Fox Foundation grant award is presented defining the impact of σ-2 receptor modulators on gene and protein expression. In two different rat models of Parkinson’s disease, the same two σ-2 receptor modulators are shown to effect pathways associated with Parkinson's disease, including cell survival, metabolism, autophagy, and protein/lipid transport.

Mary Hamby, Ph.D., Cognition’s VP of research, explained, “These findings help to broaden our understanding of the role of the σ-2 receptor in central nervous system diseases, and support continued discovery and development of candidates that modulate this therapeutic target for Alzheimer’s disease, dementia with Lewy bodies, and Parkinson’s disease.”

Poster details:
Title: A transcriptomic analysis to investigate the role of sigma-2 receptor modulators CT1812 and CT2168 in a mouse model of Alzheimer’s disease
Authors: Caldwell J, Cho E, Knezovich N, Caggiano AO, Di Caro V, Hamby ME
Session: Nov 15 - Session PSTR527 - Alzheimer's Disease and Dementia: Genomics and Other Omics Approaches

Title: A proteomic analysis to elucidate the role of sigma-2 receptor modulators CT1812 and CT2168 in a mouse model of Alzheimer’s disease
Authors: Cho E, Caldwell J, Pandey K, Duong DM, Seyfried NT, Caggiano AO, Di Caro V, Hamby ME
Session: Nov 15 - Session PSTR527 - Alzheimer's Disease and Dementia: Genomics and Other Omics Approaches

Title: Exploratory omics study reveals potential roles of sigma-2 receptor modulators in AAV1/2A53T-aSyn rat model of Parkinson’s disease
Authors: Reaver AJ, Lizama BN, Pandey K, Duong DM, Seyfried NT, Caggiano AO, Hamby ME
Session: Nov 14 - PSTR402 - Therapeutic Strategies: Small Molecule Therapeutics

Title: Unbiased proteomic and transcriptomic analysis of Sigma-2 receptor modulation in an in vivo model of synucleinopathy
Authors: Lizama BN, Reaver AJ, Pandey K, Duong DM, Seyfried NT, Caggiano AO, Hamby ME
Session: Nov 14 - PSTR402 - Therapeutic Strategies: Small Molecule Therapeutics

About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com 

Forward Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, including CT1812, and any expected or implied benefits or results, including that initial clinical results observed with respect to CT1812 will be replicated in later trials and our clinical development plans, including statements regarding our clinical studies of CT1812 in animal models and any analyses of the results therefrom, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impact of the COVID-19 pandemic on our business, supply chain and labor force; and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at www.sec.gov. These risks are not exhaustive, and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.